Use of Cyclodextrin and Its Derivatives as Carriers for Oligonucleotide Delivery

Antisense Research and Development

Volumn 5, Issue 3, 1995, Pages 185-192

  Zhao, Qiuyan ^a   Temsamani, Jamal ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTISENSE OLIGONUCLEOTIDE; CYCLODEXTRIN; FLUORESCENT DYE; NUCLEASE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; SULFUR 35;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG STABILITY; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MICROSCOPY; PHARMACEUTICS; PRIORITY JOURNAL; T CELL LEUKEMIA;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CYCLODEXTRINS; DRUG CARRIERS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMAN; KINETICS; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR RADIOISOTOPES; THIONUCLEOTIDES;

EID: 0028885569     PISSN: 10505261     EISSN: 15578526     Source Type: Journal    
DOI: 10.1089/ard.1995.5.185     Document Type: Article

References (30)

1. AGRAWAL, S., TEMSAMANI, J., and TANG, J.Y. (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
2. ARIMA, H., KONDO, T., IRIE, T., and UEKAMA, K. (1992). Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta cyclodextrin derivatives and formulation as oleaginous suppository. J. Pharm. Sci. 81, 1119-1125.
3. BARRY, E.L., GESEK, F.A., and FRIEDMAN, P.A. (1993). Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O. Biotechniques 15,1016-1018.
4. BAYEVER, E., IVERSEN, P., BISHOP, M., SHARP, G., TEWARY, H.K., ARNESON, M.A., PIRRUCCELLO, S.J., RUDDON, R.W., KESSINGER, A., ZOIN, G., and ARMITAGE, J.O. (1993). Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial. Antisense Res. Dev. 3,383-390.
5. BEAUCAGE, S.L. (1993). Oligodeoxyribonucleotide synthesis: Phosphoramidite approach. In: Methods in Molecular Biology: Protocols for Oligonucleotides and Analogs. S. Agrawal, ed. (Humana Press, NJ) pp. 33-62.
6. BENNETT. R.M. (1993). As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells [Review]. Antisense Res. Dev. 3,235-241.
7. BREWSTER, M.E., SIMPKINS, J.W., HORA, M.S., STERN, W.C., and BODOR, N. (1989). The potential use of cyclodextrins in parenteral formulations [Review]. J. Parent. Sci. Technol. 43, 231240.15.G.
8. CHAVANY, C., SAISON-BEHMOARAS, T., DOAN, T.L., PUISIEUX, F., COUVREUR, P., and HELENE, C. (1994). Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11, 1370-1378.
9. CLARENC, J.P., DEGOLS, G., LEONETTI, J.P., MILHAUD, P., and LEBLEU, B. (1993). Delivery of antisense oligonucleotides by poly (1-lysine) conjugation and liposome encapsulation [Review]. Anti-Cancer Drug Design 8, 81-94.
10. COSSUM, P.A., TRUONG, L., OWENS, S R., MARKHAM, P.M., SHEA, J.P., and CROOKE, S.T. (1994). Pharmacokinetics of a relabeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94.
11. FRULINK, H.W., VISSER, J., HEITING, N.R., OOSTING, R., MEI-JER, D.K., and LERK, C.F. (1990). The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat. Pharm. Res. 7,1248-1252.
12. HORIUCHI, Y., HIRAYAMA, F., and UEKAMA, K. (1990). Slow-re-lease characteristics of diltiazem from ethylated beta-cyclodextrin complexes. J. Pharm. Sci. 79,128-132.
13. IVERSEN, P.L., CROUSE, D., ZON, G., and PERRY, G. (1992). Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible. Antisense Res. Dev. 2, 223-233.
14. JANSEN, T., XHONNEUX, B., MESENS, J., and BORGERS, M. (1990). Beta-cyclodextrins as vehicles in eye-drop formulations: An evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxicity Res. 7,459-468.
15. JULLANO, R.L., and AKHTAR, S. (1992), Liposomes as a drug delivery system for antisense oligonucleotides [Review]. Antisense Res. Dev. 2, 165-176.
16. KRIEG, A M., TONKINSON, J., MATSON, S., ZHAO, Q., SAXON, M., ZHANG, L.M., BHANJA, U.L., YAKUBOV, L., and STEIN, C.A. (1993). Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. USA 90, 1048-1052.
17. LEONETTI, J.P., MECHTI, N., DEGOLS, G., GAGNOR, C., and LEBLEU, B. (1991). Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 88, 2702-2706.
18. MERKUS, F.W., VERHOEF, J.C., ROMEIJN, S.G., and SCHIPPER, N.G. (1991). Absorption enhancing effect of cyclodextrins on in-tranasally administered insulin in rats. Pharm. Res. 8,588-592.
19. PARDRIDGE, W.M., and BOADO, R.J. (1991). Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein. FEBS Lett. 288,30-32.
20. PHILLIPS, N.C., and EMILI, A. (1991). Immunogenicity of immunoli-posomes. Immunol. Lett. 30,291-296.
21. SCHUBERT, F., AHLERT, K., CECH, D., and ROSENTHAL, A. (1990). One-step labelling of oligonucleotides with fluorescein during automated synthesis. Nucleic Acids Res. 18,3427.
22. STEIN, C.A., and CHENG, Y.C. (1993). Antisense oligonucleotides as therapeutic agents—Is the bullet really magical? [Review]. Science 261,1004-1012.
23. STEIN, C.A., IVERSEN, P.L., SUBASINGHE, C., COHEN, J.S., STEC, W.J., and ZON, G. (1990). Preparation of 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. Anal. Biochem. 188,11-16.
24. TEMSAMANI, J., KUBERT, M., TANG, J.Y., PADMAPRIYA, A., and AGRAWAL, S. (1994). Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. 4, 35-42.
25. WEINER, D.B., WILLIAMS, W.V., WEISZ, P.B., and GREEN, M.I. (1992). Synthetic cyclodextrin derivatives inhibit HIV infection in vitro. Pathobiology 60,206-212.
26. WENZ, G. (1994). Cyclodextrin as building blocks for supramolecular structures and functional units. Angew. Chem. Int. Ed. Engl. 33, 803-822.
27. YEOMAN, L.C., DANELS, Y.J., and LYNCH, M.J. (1992). Lipofectin enhances cellular uptake of antisense DNA while inhibiting tumor cell growth. Antisense Res. Dev. 2,51-59.
28. ZAMECNIK, P., AGHAJANIAN, J., ZAMECNIK, M., GOODCHILD, J., and WITMAN, G. (1994). Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc. Natl. Acad. Sci. USA 91,3156-3160.
29. ZHANG, R., SHAHINL\N, H., YAN, J., AMIN, G., LU, Z., JL-iNG, Z., TEMSAMANI, J., SAAG, M.S., SCHECHTER, P.S., AGRAWAL, S., and DIASIO, R.B. (1995). Human pharmacokinetics of anti-HIV antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected individuals. Clin. Pharmacol. Ther. 58,44-53.
30. ZHAO, Q., MATSON, S., HERRERA. C.J., FISHER, E., YU, H., and KREIG, A.M. (1993). Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3,53-66.